Ready to submit? Start a new submission or continue a submission in progress

Go to submission site (link opens in a new window)

Journal overview

*Please note that Expert Opinion on Orphan Drugs converted to a full Open Access journal from Volume 11 (2023). Previous
volumes will continue to provide access through a Pay to Read model.

Expert Opinion on Orphan Drugs [e-ISSN 2167-8707] is an international journal publishing rigorously peer-reviewed review articles and original papers on rare diseases and orphan drugs. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development.

Expert Opinion on Orphan Drugs aims to draw a spotlight on diseases that do not have a high prevalence but have a huge impact on patients and their clinicians, through valuable and high-quality expert insights. In a field which is ever-growing and changing, Expert Opinion on Orphan Drugs is committed to acting as a reliable beacon of guidance and support for researchers, clinicians, patients and advocacy groups in order to optimise research, development, management and quality of life of rare disease patients.

Articles focus on the following key areas:

  • Diagnostics, pharmacogenomics and screening;
  • Public health and epidemiology;
  • Drug development;
  • Lead generation and discovery;
  • Early or late phase clinical trials;
  • Regulatory issues;
  • Post-marketing safety and treatment outcomes.

The journal also welcomes solicited and unsolicited papers including Drug Evaluations, specifically reviewing the pharmacological properties, clinical potential/clinical efficacy, safety and, if applicable, HE/OR data on a particular orphan drug, as well as Original Research papers and Editorials.

Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees.

Read the Instructions for Authors for information on how to submit your article. For any pre-submission enquiries, please contact the Commissioning Editor.

Please note, from 2023 the Print ISSN is not in active use as this journal is no longer published in print.

Read full aims and scope

Explore articles

Explore the most recently published articles

Shyam Sundar et al.
Review Article |
Open Access
Ying Gao et al.
Review Article |
Open Access
Open Access
Eric D. Marsh et al.
Article |
Open Access

Latest issues

Associated journals

 

Updates

Journal news & offers

Discuss your submission with Commissioning Editor Felicity Poole

Advertise in this journal

Reach an engaged target audience and position your brand alongside authoritative peer-reviewed research by advertising in Expert Opinion on Orphan Drugs.

Explore advertising options